Bluesky Facebook Reddit Email

Diabetic ketoacidosis threatens hospitalized patients with COVID-19

06.18.20 | The Endocrine Society

Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

WASHINGTON--Diabetic ketoacidosis is a common and potentially fatal complication in hospitalized patients with COVID-19, according to a new clinical perspective published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

Diabetic ketoacidosis almost always requires special care in the hospital which usually takes place in the intensive care unit (ICU). It is caused by insufficient insulin circulating in the bloodstream, which is more likely to occur during a serious infection like COVID-19. Diabetic ketoacidosis causes a buildup of acids in the blood, leading to serious illness characterized by dehydration and sometimes difficulty breathing.

"People with diabetes who are infected with COVID-19 are at increased risk of severe disease, which in some cases is accompanied by diabetic ketoacidosis," said the paper's corresponding author Marie McDonnell, M.D., of Brigham and Women's Hospital and Harvard Medical School in Boston, Mass. "Hospitals and clinicians need to be able to quickly identify and manage diabetic ketoacidosis in COVID patients to save lives. This involves determining the options for management (including when less intensive subcutaneous insulin is indicated) and understanding how to guide patients on avoiding this serious complication."

The authors outline simpler methods of diabetic ketoacidosis management with the goal of keeping ICU beds available for severe COVID-19 cases. They advocate, in select cases, for diabetic ketoacidosis protocols that use subcutaneous insulin therapy outside of the ICU instead of IV insulin therapy in the ICU to protect nurses from having to deliver frequent bedside care to COVID-infected patients.

Other topics include the importance of recognizing euglycemic ketoacidosis in those taking SGLT2-inhibitor agents and the recognition that unique approaches, including telemedicine, may be needed to help the highest risk patients avoid ketoacidosis.

###

Other authors include Nadine E. Palermo of Brigham and Women's Hospital and Harvard Medical School and Archana R. Sadhu of Houston Methodist Hospital and Weill Cornell Medical College in Houston, Texas. The manuscript did not receive external funding.

The manuscript, "Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations," was published online, ahead of print.

Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at? http://www.endocrine.org . Follow us on Twitter at @TheEndoSociety and @EndoMedia.

The Journal of Clinical Endocrinology & Metabolism

Keywords

Article Information

Contact Information

Colleen Williams
cwilliams@endocrine.org

How to Cite This Article

APA:
The Endocrine Society. (2020, June 18). Diabetic ketoacidosis threatens hospitalized patients with COVID-19. Brightsurf News. https://www.brightsurf.com/news/LN26NV41/diabetic-ketoacidosis-threatens-hospitalized-patients-with-covid-19.html
MLA:
"Diabetic ketoacidosis threatens hospitalized patients with COVID-19." Brightsurf News, Jun. 18 2020, https://www.brightsurf.com/news/LN26NV41/diabetic-ketoacidosis-threatens-hospitalized-patients-with-covid-19.html.